Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Analysis of tisagenlecleucel in B-cell NHL in BELINDA

Jason Westin, MD, FACP, University of Texas MD Anderson Center, Houston, TX, presents findings from the Phase III BELINDA (NCT03570892) trial of tisagenlecleucel (tisa-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, with the aim of moving tisa-cel to second-line therapy from third-line therapy. The primary endpoint of event-free survival was not met, despite other CAR T-cell therapies having success in similar trials. Further analysis of the trial design will elucidate the causes of the results and Dr Westin highlights the practicality of tisa-cel in its current indications. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.